Who signed the AEMD 8-K related to the warrant exercises?

The report was signed on behalf of Aethlon Medical, Inc. by James B. Frakes, who is identified as the company’s Chief Executive Officer and Chief Financial Officer.

Aethlon Medical reports 1,604,095 shares out

Q: What did AEMD announce regarding its share count on August 28, 2026?

Aethlon Medical, Inc. announced that it has 1,604,095 shares of common stock outstanding as of the close of business on August 28, 2026, following the recent exercise of certain pre-funded warrants.

Q: What happened to AEMD’s pre-funded warrants according to this 8-K?

Aethlon Medical, Inc. reported that all previously outstanding pre-funded warrants have been exercised, meaning no pre-funded warrants remain outstanding after the recent exercises.

Q: Does AEMD specify the date for the updated shares outstanding figure?

Yes. Aethlon Medical, Inc. states that the 1,604,095 shares of common stock outstanding figure is as of the close of business on August 28, 2026.

AETHLON MEDICAL INC (AEMD) reported an update on its capital structure.

Filing Impact

(High)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

8-K

Rhea-AI Filing Summary

AETHLON MEDICAL INC (AEMD) reported an update on its capital structure. Following recent exercises of certain pre-funded warrants, the company has 1,604,095 shares of common stock outstanding as of the close of business on August 28, 2026. The company states that, as a result of these exercises, all previously outstanding pre-funded warrants have been exercised, leaving no such warrants remaining outstanding.

Filing Explained

The completed exercises converted the remaining pre-funded warrants into common shares, leaving no such warrants available for future conversion; issuing those shares increases the total share count and reduces existing holders’ percentage ownership absent offsetting changes.

8-K Event Classification

Item 8.01 — Other Events

1 item

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Key Figures

Common stock outstanding: 1,604,095 shares

1 metrics

Common stock outstanding 1,604,095 shares As of the close of business on August 28, 2026

Key Terms

pre-funded warrants, Emerging growth company, Nasdaq Capital Market

3 terms

pre-funded warrants financial

"Following recent exercises of certain pre-funded warrants, Aethlon Medical, Inc."

Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.

Emerging growth company regulatory

"Emerging growth company"

An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.

Nasdaq Capital Market market

"AEMD | | The Nasdaq Capital Market"

The Nasdaq Capital Market is a platform where smaller, emerging companies can list their shares for trading by investors. It provides these companies with access to funding and visibility, helping them grow, much like a local marketplace where new vendors can introduce their products to potential customers. For investors, it offers opportunities to discover early-stage companies with growth potential.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What happened to AEMD’s pre-funded warrants according to this 8-K?

Aethlon Medical, Inc. reported that all previously outstanding pre-funded warrants have been exercised, meaning no pre-funded warrants remain outstanding after the recent exercises.

Does AEMD specify the date for the updated shares outstanding figure?

Yes. Aethlon Medical, Inc. states that the 1,604,095 shares of common stock outstanding figure is as of the close of business on August 28, 2026.

What is the trading symbol and market for AEMD’s common stock?

Aethlon Medical, Inc.’s common stock, par value $0.001 per share, trades under the symbol AEMD on The Nasdaq Capital Market.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Available on EDGAR 08/31/2026 - 09:16 AM Accepted by SEC EDGAR 08/31/2026 - 09:15 AM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 28, 2026

Aethlon Medical, Inc.

(Exact name of registrant as specified in its charter)

Nevada	001-37487	13-3632859
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

11555 Sorrento Valley Road, Suite 203

San Diego, California

92121

(Address of principal executive offices)

(Zip Code)

Registrant’s telephone number, including area code: (619) 941-0360

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.001 par value per share		AEMD		The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

Following recent exercises of certain pre-funded warrants, Aethlon Medical, Inc. has 1,604,095 shares of common stock outstanding as of the close of business on August 28, 2026. As such, all previously outstanding pre-funded warrants have been exercised.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: August 31, 2026	Aethlon Medical, Inc.

	By:	/s/ James B. Frakes
	Name:	James B. Frakes Chief Executive Officer and Chief Financial Officer

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

3 documents